Effect of Trelagliptin on Vascular Endothelial Functions and Serum Adiponectin Level in Patients with Type 2 Diabetes: a Preliminary Single-arm Prospective Pilot Study

Overview

Journal Cardiovasc Diabetol

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
Endocrinology

Date 2016 Nov 5

PMID 27809903

Citations 14

Authors

Satoshi Ida

Kazuya Murata

Katunori Betou

Chiaki Kobayashi

Yuki Ishihara

Kanako Imataka

Akihiro Uchida

Kou Monguchi

Ryutaro Kaneko

Ryoko Fujiwara

Hiroka Takahashi

Affiliations

Soon will be listed here.

Abstract

Background: Trelagliptin, an oral DPP-4 inhibitor, which is administered once per week and characterized by a long half-life in blood. The effects of trelagliptin on vascular endothelial functions have not been clarified to date. The objective of the present study was to examine the effects of trelagliptin on vascular endothelial functions in patients with type 2 diabetes mellitus (DM) using flow-mediated dilatation (FMD), adiponectin, and asymmetric dimethylarginine (ADMA) as evaluation indicators.

Methods: This study was a preliminary single-arm prospective pilot study. The subjects of this study were type 2 DM patients aged 20-74 years, who visited our outpatient department. The patients were treated with trelagliptin, and their FMD, adiponectin, and ADMA levels were measured at baseline and at 12 weeks after initial treatment to determine the changes during the study period.

Results: A total of 27 patients, excluding three dropouts, were included in the population for analysis. Trelagliptin treatment showed no significant changes in FMD (2.42 ± 2.7% at baseline vs. 2.66 ± 3.8% post-treatment, P = 0.785) and ADMA (0.41 ± 0.0 µg/mL at baseline vs. 0.40 ± 0.0 µg/mL post-treatment, P = 0.402). Trelagliptin treatment resulted in a significant increase of serum adiponectin level (7.72 ± 6.9 µg/mL at baseline vs. 8.82 ± 8.3 µg/mL post-treatment, P < 0.002).

Conclusions: In this pilot study, trelagliptin treatment showed no significant changes in FMD. On the other hand, it was believed that trelagliptin treatment may increase serum adiponectin level. Trial Registration http://www.umin.ac.jp (Trial ID UMIN000018311).

Citing Articles

A Comprehensive Review of Clinical Studies Applying Flow-Mediated Dilation.

Ahn Y, Aung N, Ahn H Diagnostics (Basel). 2024; 14(22).

PMID: 39594169 PMC: 11592698. DOI: 10.3390/diagnostics14222499.

Teneligliptin, a DPP-4 Inhibitor, Improves Vascular Endothelial Function via Divergent Actions Including Changes in Circulating Endothelial Progenitor Cells.

Akashi N, Umemoto T, Yamada H, Fujiwara T, Yamamoto K, Taniguchi Y Diabetes Metab Syndr Obes. 2023; 16:1043-1054.

PMID: 37077576 PMC: 10108873. DOI: 10.2147/DMSO.S403125.

Plasma Nitrate Levels Are Related to Metabolic Syndrome and Are Not Altered by Treatment with DPP-4 Inhibitor Linagliptin: A Randomised, Placebo-Controlled Trial in Patients with Early Type 2 Diabetes Mellitus.

Reijrink M, De Boer S, van Roon A, Slart R, Fernandez B, Feelisch M Antioxidants (Basel). 2021; 10(10).

PMID: 34679685 PMC: 8533083. DOI: 10.3390/antiox10101548.

DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.

Zhang J, Chen Q, Zhong J, Liu C, Zheng B, Gong Q Front Immunol. 2019; 10:1050.

PMID: 31134095 PMC: 6526751. DOI: 10.3389/fimmu.2019.01050.

Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis.

Batzias K, Antonopoulos A, Oikonomou E, Siasos G, Bletsa E, Stampouloglou P J Diabetes Res. 2019; 2018:1232583.

PMID: 30622967 PMC: 6304901. DOI: 10.1155/2018/1232583.

References

Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K . Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group.... Cardiovasc Diabetol. 2014; 13:65. PMC: 4021346. DOI: 10.1186/1475-2840-13-65. View

Kishida K, Funahashi T, Shimomura I . Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab. 2014; 28(1):119-30. DOI: 10.1016/j.beem.2013.08.006. View

Derosa G, Carbone A, Franzetti I, Querci F, Fogari E, Bianchi L . Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract. 2012; 98(1):51-60. DOI: 10.1016/j.diabres.2012.05.022. View

Sibal L, Agarwal S, Home P, Boger R . The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr Cardiol Rev. 2011; 6(2):82-90. PMC: 2892080. DOI: 10.2174/157340310791162659. View

Ayaori M, Iwakami N, Uto-Kondo H, Sato H, Sasaki M, Komatsu T . Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc. 2013; 2(1):e003277. PMC: 3603233. DOI: 10.1161/JAHA.112.003277. View

Lundby-Christensen L, Tarnow L, Boesgaard T, Lund S, Wiinberg N, Perrild H . Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial. BMJ Open. 2016; 6(2):e008376. PMC: 4771973. DOI: 10.1136/bmjopen-2015-008376. View

Derosa G, Maffioli P, Salvadeo S, Ferrari I, Ragonesi P, Querci F . Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism. 2009; 59(6):887-95. DOI: 10.1016/j.metabol.2009.10.007. View

Margaritis M, Antonopoulos A, Digby J, Lee R, Reilly S, Coutinho P . Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels. Circulation. 2013; 127(22):2209-21. DOI: 10.1161/CIRCULATIONAHA.112.001133. View

Mason R, Jacob R, Kubant R, Walter M, Bellamine A, Jacoby A . Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. J Atheroscler Thromb. 2011; 18(9):774-83. DOI: 10.5551/jat.7666. View

10.

Koska J, Schwartz E, Mullin M, Schwenke D, Reaven P . Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care. 2010; 33(5):1028-30. PMC: 2858168. DOI: 10.2337/dc09-1961. View

11.

Sakr H . Effect of sitagliptin on the working memory and reference memory in type 2 diabetic Sprague-Dawley rats: possible role of adiponectin receptors 1. J Physiol Pharmacol. 2013; 64(5):613-23. View

12.

Tsuchiya K, Akaza I, Yoshimoto T, Hirata Y . Pioglitazone improves endothelial function with increased adiponectin and high-density lipoprotein cholesterol levels in type 2 diabetes. Endocr J. 2009; 56(5):691-8. DOI: 10.1507/endocrj.k08e-308. View

13.

Cooke J . Does ADMA cause endothelial dysfunction?. Arterioscler Thromb Vasc Biol. 2000; 20(9):2032-7. DOI: 10.1161/01.atv.20.9.2032. View

14.

Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K . Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin. 2011; 27(9):1781-92. DOI: 10.1185/03007995.2011.599371. View

15.

Lopez-Jaramillo P . The Role of Adiponectin in Cardiometabolic Diseases: Effects of Nutritional Interventions. J Nutr. 2016; 146(2):422S-426S. DOI: 10.3945/jn.114.202432. View

16.

Forstermann U, Munzel T . Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006; 113(13):1708-14. DOI: 10.1161/CIRCULATIONAHA.105.602532. View

17.

Naka K, Papathanassiou K, Bechlioulis A, Kazakos N, Pappas K, Tigas S . Determinants of vascular function in patients with type 2 diabetes. Cardiovasc Diabetol. 2012; 11:127. PMC: 3490819. DOI: 10.1186/1475-2840-11-127. View

18.

Kawano N, Emoto M, Mori K, Yamazaki Y, Urata H, Tsuchikura S . Association of endothelial and vascular smooth muscle dysfunction with cardiovascular risk factors, vascular complications, and subclinical carotid atherosclerosis in type 2 diabetic patients. J Atheroscler Thromb. 2011; 19(3):276-84. DOI: 10.5551/jat.10629. View

19.

Miyagawa K, Kondo T, Goto R, Matsuyama R, Ono K, Kitano S . Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes. Cardiovasc Diabetol. 2013; 12:160. PMC: 4176757. DOI: 10.1186/1475-2840-12-160. View

20.

Fox C, Golden S, Anderson C, Bray G, Burke L, de Boer I . Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care. 2015; 38(9):1777-803. PMC: 4876675. DOI: 10.2337/dci15-0012. View